Grignano E, et al. - In this retrospective review, researchers assessed the role of radiotherapy (RT) as salvage and/or consolidation therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Post-irradiation follow-up for a median 36 months revealed 5-year progression-free survival (PFS) and overall survival (OS) to be 62% and 72%, respectively. Overall, radiotherapy was found to have low toxicity and ease of use and therefore, should continue to be considered as a treatment option for patients with R/R DLBCL or as consolidation therapy in patients with high-risk disease, mostly in patients with chemo-sensitive disease or bulky disease.